

## WHAT IS CLAIMED IS:

1. A substantially pure peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs. 1-30, said peptide being operably linked to a molecule which enhances its therapeutic effectiveness.

5        2. A substantially pure peptide according to Claim 1 wherein said peptide modulates at least one of the following conditions: immune activity, hepatitis infection, hepatitis B infection, the extent of nephritis, the growth of a cancer, or body weight.

10       3. The substantially pure peptide of Claim 2, wherein said molecule which enhances said therapeutic effectiveness is not a peptide which is adjacent to said peptide of SEQ ID NOs. 1-30 in a naturally occurring peptide.

15       4. The substantially pure peptide of Claim 3, wherein said molecule which enhances said therapeutic effectiveness has an effect selected from the group consisting of a prolonged effect, a shortened effect, a delayed onset of effect, a hastened onset of effect, an increased intensity of effect, a decreased intensity of effect, a reduction in side effects, the creation of one or more effects, a delayed subsiding of effect, a hastened subsiding of effect and a targeting of the peptide to a discrete location within an individual.

20       5. The substantially pure peptide of Claim 4, wherein said molecule which enhances said therapeutic effect is selected from the group consisting of an organic compound, a carbohydrate, a sugar, a polysaccharide, an amino acid, an amino acid polymer, a peptide, a steroid, a protein, an isolated domain of a protein, a lipid molecule, a fatty acid, a bile acid, a polyamine, a protease inhibitor and a combination of any of the preceding molecules.

25       6. The substantially pure peptide of Claim 4, wherein said molecule which enhances said therapeutic effect is operably linked to said peptide via a covalent bond or a non-covalent interaction.

30       7. A substantially pure peptide comprising a functional derivative of a biologically active peptide, said biologically active peptide having an amino acid selected from the group consisting of SEQ ID NOs. 1-30, said peptide being operably linked to a molecule which enhances its therapeutic effectiveness.

35       8. A substantially pure peptide according to Claim 7 wherein said peptide modulates at least one of the following conditions: immune activity, hepatitis infection, hepatitis B infection, the extent of nephritis, the growth of a cancer, or body weight.

9. The substantially pure peptide of Claim 8, wherein said molecule which enhances said therapeutic effectiveness is not a peptide which is adjacent to said peptide of SEQ ID NOs. 1-30 or said functional derivative in a naturally occurring peptide.

10. The substantially pure peptide of Claim 9, wherein said molecule which enhances said therapeutic effectiveness has an effect selected from the group consisting of a prolonged effect, a shortened effect, a delayed onset of effect, a hastened onset of effect, an increased intensity of effect, a decreased intensity of effect, a reduction in side effects, the

creation of one or more effects, a delayed subsiding of effect, a hastened subsiding of effect and a targeting of the peptide to a discrete location within an individual.

11. The substantially pure peptide of Claim 10, wherein said molecule which enhances said therapeutic effect is, selected from the group consisting of an organic compound, a carbohydrate, a sugar, a polysaccharide, an amino acid, an amino acid polymer, a peptide, a steroid, a protein, an isolated domain of a protein, a lipid molecule, a fatty acid, a bile acid, a polyamine, a protease inhibitor and a combination of any of the preceding molecules.

12. The substantially pure peptide of Claim 10, wherein said molecule which enhances said therapeutic effect is operably linked to said peptide via a covalent bond or a non-covalent interaction.

13. A pharmaceutical composition comprising a substantially pure peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs. 1-30, said peptide being operably linked to a molecule which enhances its therapeutic effectiveness.

14. A composition according to Claim 13 wherein said peptide modulates at least one of the following conditions: immune activity, hepatitis infection, hepatitis B infection, the extent of nephritis, the growth of a cancer, or body weight.

15. The composition of Claim 14, wherein said molecule which enhances said therapeutic effectiveness is not a peptide which is adjacent to said peptide of SEQ ID NOs. 1-30 in a naturally occurring peptide.

16. The composition of Claim 15, wherein said molecule which enhances said therapeutic effectiveness has an effect selected from the group consisting of a prolonged effect, a shortened effect, a delayed onset of effect, a hastened onset of effect, an increased intensity of effect, a decreased intensity of effect, a reduction in side effects, the creation of one or more effects, a delayed subsiding of effect, a hastened subsiding of effect and a targeting of the peptide to a discrete location within an individual.

17. The composition of Claim 16, wherein said molecule which enhances said therapeutic effect is selected from the group consisting of an organic compound, a carbohydrate, a sugar, a polysaccharide, an amino acid, an amino acid polymer, a peptide, a steroid, a protein, an isolated domain of a protein, a lipid molecule, a fatty acid, a bile acid, a polyamine, a protease inhibitor and a combination of any of the preceding molecules.

18. The composition of Claim 16, wherein said molecule which enhances said therapeutic effect is operably linked to said peptide via a covalent bond or a non-covalent interaction.